Brief: Nabriva Extends Exclusive Agreement To Promote And Distribute Sivextro (Tedizolid Phosphate) In The U.S. Through The End Of 2026
05/05/2022 13:22
May 5 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA EXTENDS EXCLUSIVE AGREEMENT TO PROMOTE AND
DISTRIBUTE
SIVEXTRO® (TEDIZOLID PHOSPHATE) IN THE U.S. THROUGH THE END OF
2026
* NABRIVA THERAPEUTICS PLC - TERM OF AGREEMENT CAN BE
FURTHER
EXTENDED BY AN ADDITIONAL THREE-YEAR PERIOD, SUBJECT TO MUTUAL
AGREEMENT
Source text for Eikon: ID:nGNX1pq1B7
Further company coverage: NBRV.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update